<?xml version="1.0" encoding="UTF-8"?>
<p id="p0145">Ribavirin is also a broad-spectrum drug whose therapeutic potential was uncovered during 1972. This antiviral drug is used in the treatment of hepatitis C. It is usually used in combination with interferon α (IFN). This drug, approved by the FDA, competes for the active site of RdRp. Ribavirin scored 109.5 μM of half maximal concentration against SARS-CoV-2 (
 <xref rid="bb0210" ref-type="bibr">Elfiky, 2020</xref>).
</p>
